Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
S
Steven A. Schichman
High Impact
Researcher
Also affiliated: California Institute of Technology (1979); Harvard University (2020); VA Boston Healthcare System (2017); University of California San Diego (1979); University of Chicago (1978–1979); Central Arkansas Veterans Healthcare System (2001–2023); VA Greater Los Angeles Healthcare System (2017)
Faculty Researcher
24 h-index
44 pubs
1,903 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Steven A. Schichman investigates the intersection of traumatic stress, aging, and epigenetic modifications. His research explores how conditions such as post-traumatic stress disorder (PTSD) and alcohol use disorders may influence the biological pace of cellular aging.
His work includes examining the effects of pharmacogenomic testing on medication selection and symptom remission in major depressive disorder. Schichman's recent publications detail longitudinal studies on cellular and cognitive aging related to traumatic stress. He has published 44 papers, which have been cited approximately 1,885 times, contributing to his h-index of 24. He is recognized as a highly cited researcher. Key collaborators include Jeffrey M. Pyne at the University of Arkansas for Medical Sciences, with whom he has co-authored one publication.
Metrics
- h-index: 24
- Publications: 44
- Citations: 1,903
Selected Publications
-
Longitudinal study of traumatic-stress related cellular and cognitive aging (2023)
-
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder (2022)
-
A unique presentation of unilateral pleural effusion in a patient with a high-grade plasma cell neoplasm (2015)
-
ATM Gene Point Mutation and Frameshift Mutation Are Found In High-Risk, Untreated Chronic Lymphocytic Leukemia Patients with Interstitial Deletion of Chromosome 11q and Uniparental Disomy of Chromosome 11q (2010)
-
Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome. (2009)
-
Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients. (2009)
-
Development of Essential Thrombocythemia-Like Myeloproliferative Disorder in Transgenic Mice Overexpressing a Human 8-Oxoguanine DNA-Glycosylase Gene. (2004)
-
Epstein-Barr Virus (EBV) DNA in Plasma Is Not Encapsidated in Patients With EBV-Related Malignancies (2004)
-
HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: A further expansion of the disease spectrum (2004)
-
The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype (2003)
-
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium (2003)
-
Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death (2003)
-
Linezolid‐Induced Pure Red Blood Cell Aplasia (2002)
-
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (2001)
-
Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data (2001)
Collaboration Network
Top Collaborators
Annjanette Stone
Central Arkansas Veterans Healthcare System (US)
2 shared publications
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
- Longitudinal study of traumatic-stress related cellular and cognitive aging
David W. Oslin
Philadelphia VA Medical Center (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Kevin G. Lynch
University of Pennsylvania (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Mei‐Chiung Shih
Stanford University (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Erin Ingram
Philadelphia VA Medical Center (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Laura O. Wray
University at Buffalo, State University of New York (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Sara R. Chapman
VA Pittsburgh Healthcare System (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Henry R. Kranzler
University of Pennsylvania (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Joel Gelernter
VA Connecticut Healthcare System (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Jeffrey M. Pyne
University of Arkansas for Medical Sciences
1 shared publication
In database
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Scott L. DuVall
VA Salt Lake City Healthcare System (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Lisa Soleymani Lehmann
Google (United States) (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Michael E. Thase
Philadelphia VA Medical Center (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Muhammad Aslam
Cincinnati VA Medical Center (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Steven L. Batki
San Francisco VA Health Care System (US)
1 shared publication
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Similar Researchers
Based on overlapping research topics
Navdeep Dogra
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Disease Mechanisms Research
Matthew Plotkin
University of Arkansas for Medical Sciences
Epigenetics and DNA Methylation
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Anna Brickell
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Disease Mechanisms Research
Li Xia
National Center for Toxicological Research
Epigenetics and DNA Methylation
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Ronald G. Jones
University of Arkansas at Fayetteville
Aging and Longevity in Model Organisms
Metabolism and Genetic Disorders
Disease Mechanisms Research
Sankalpa Chakraborty
Arkansas State University
Aging and Longevity in Model Organisms
Metabolism and Genetic Disorders
Disease Mechanisms Research